ArriVent BioPharma, Inc. (AVBP) vs Taysha Gene Therapies, Inc. (TSHA)
ArriVent BioPharma, Inc. and Taysha Gene Therapies, Inc. are both Biotechnology companies. ArriVent BioPharma, Inc. and Taysha Gene Therapies, Inc. are of similar size ($1.6B and $1.5B). Across the 9 metrics below, Taysha Gene Therapies, Inc. leads on 6 and ArriVent BioPharma, Inc. on 3.
Valuation
Profitability
| Metric | AVBP | TSHA | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 100.00% | 65.16% |
| Operating margin | 0.00% | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% | 0.00% |
| Free cash flow margin | 0.00% | 0.00% | 0.00% |
| Return on equity | (53.10%) | (47.05%) | (57.72%) |
| Return on assets | (49.30%) | (37.23%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack